Faced with the shortage of ozempic (or semaglutide), two associations of patients suffering from diabetes and/or obesity are taking a stand.
- The French Federation of Diabetics and the CNAO (National Collective of Obese Associations) are taking a position on the thorny situation generated by the shortage of ozempic.
- “It is unacceptable that patients suffering from type 2 diabetes cannot benefit from their treatments or are placed in competition with patients suffering from obesity, just as it is unbearable that this effective treatment is not yet accessible to people suffering from obesity”, estimate the two patient associations.
- They also recall the causes of the ozempic shortage.
“Semaglutide (ozempic): let’s stop pitting patients against each other!” In a joint press release, the French Federation of Diabetics And the CNAO (National Collective of Obese Associations) take a position on the thorny situation generated by the shortage of ozempic.
Diabetes and obesity: what are the causes of ozempic ruptures?
According to recent studies carried out by the Novo Nordisk laboratory, semaglutide (a molecule belonging to the class of GLP-1 analogues and already used in the context of type 2 diabetes), reduces cardiovascular risk in people with obesity. “This is a real discovery, especially if we remember that the World Health Organization (WHO) estimates that 29% of the French population will be obese in 2030 compared to 17% to date.” write the two patient associations. “This recent information generates new supply tensions and provokes opposition between patients suffering from type 2 diabetes and obesity,” deplore the activists.
For the CNAO and the French Diabetics Federation, semaglutide ruptures are also caused by the following elements:
– The non-coverage of Ozempic® by Health Insurance in the obesity indication.
– The frenzied communication on the molecule and its slimming effects from the media and especially social networks, which has led to an increase in demand of more than 25% in France in one year.
– The inability of manufacturers to keep up with the increase in demand.
– The absence of reimbursement in France for semaglutide Wegowy® (Novo Nordisk) indicated for obesity, due to delays in negotiations between the manufacturer and the public authorities.
Ozempic: “patients with diabetes and obesity must have access to it”
“It is unacceptable that patients suffering from type 2 diabetes cannot benefit from their treatments or are placed in competition with patients suffering from obesity, just as it is unbearable that this effective treatment is not yet accessible to people suffering from obesity, which is today the 4th risk factor for death according to the WHO”, insist the activists.
The Federation and the CNAO are finally demanding true recognition of “obesity pathology” by the French state, which is itself associated with 19 other diseases (including diabetes).
